During Thursday’s Current trade, Shares of Lexicon Pharmaceuticals, Inc.(NASDAQ:LXRX), lost -0.98% to $12.10.
Lexicon Pharmaceuticals, Inc. (LXRX) declared that data from its pivotal TELESTAR Phase 3 clinical study of telotristat etiprate has been accepted as a late-breaking presentation at the European Cancer Congress, which will be held September 25–29 in Vienna, Austria.
Telotristat etiprate, which has received Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration, is in development for the treatment of carcinoid syndrome in cancer patients whose symptoms are not adequately controlled with the current standard of care.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases. Its drug development programs comprise telotristat etiprate, an orally-delivered small molecule drug candidate, which is in Phase III clinical trials for the treatment of carcinoid syndrome.
Shares of Platform Specialty Products Corp(NYSE:PAH), declined -3.52% to $14.26, during its current trading session.
Platform Specialty Products Corporation (PAH) declared that it had received antitrust clearance from the Federal Cartel Office in Germany in connection with its formerly-declared recommended offer to acquire all of the issued and outstanding shares of Alent plc in a cash and stock transaction for about $2.1 billion1 (the “Alent Acquisition”) by way of a court-sanctioned scheme of arrangement under the U.K. Companies Act 2006 (the “Scheme”).
The Alent Acquisition remains subject to the sanction of the U.K. court and certain other closing conditions and approvals set forth in the Scheme, counting, among others, regulatory approvals in certain other foreign jurisdictions. As of recently, in addition to the approval in Germany, Platform has received notice of the early termination of the antitrust waiting period under the U.S. Hart-Scott Rodino Antitrust Improvements Act and approval from the South Korean regulatory authorities. The Alent Acquisition is predictable to close in late 2015 or early 2016. Following closing of the Alent Acquisition, Platform will remain a New York Stock Exchange listed company domiciled in the United States.
Platform Specialty Products Corporation produces and sells specialty chemical products in the Americas, Asia, and Europe. The company’s Performance Materials segment manufactures and markets plating products that are used to plate holes; final finishes, which are used on printed circuit boards; circuit formation products to promote adhesion and form circuit patterns; oxides that are used in the fabrication of multilayer circuit boards; and pre-treatment and cleaning solutions.
Endo International plc - Ordinary Shares(NASDAQ:ENDP), during its Thursday’s current trading session decreased -5.60% to $71.18.
Endo Pharmaceuticals Inc., a partner of Endo International plc (ENDP) (ENL.TO), and BioDelivery Sciences International, Inc. (BDSI) presented data from a Phase 2 study for the investigational drug buprenorphine HCl buccal film utilizing BDSI’s patented BioErodible MucoAdhesive (BEMA®) drug delivery technology. The findings, presented in a poster session at PAINWeek 2015 in Las Vegas , showed that study participants receiving around-the-clock therapy with an opioid full agonist (morphine or oxycodone) could be switched to buprenorphine HCl buccal film, at about half the full agonist dose, without increasing the risk of experiencing opioid withdrawal or a loss of pain relief. These findings also will be presented later this month at the 26th Annual Meeting of the American Academy of Pain Administration in National Harbor, MD.
Buprenorphine HCl buccal film is being developed under the proprietary name BELBUCA™ (buprenorphine HCl) buccal film and is presently under review by the U.S. Food and Drug Administration (FDA) for use in patients with pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The PDUFA action date is in October 2015.
Endo International plc, a specialty healthcare company, focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
